NMT MEDICAL COMPLETES MIGRAINE STUDY ENROLLMENT
NMT Medical has announced that it recently completed patient enrollment in its MIST (Migraine Intervention with STARFlex Technology) clinical trial. The trial enrolled 147 migraine headache patients at 16 participating centers in the UK. MIST is designed to evaluate the effectiveness of NMT's STARFlex implant technology in treating migraine patients. Enrollees were randomized to receive the implant or were assigned to a control group. NMT expects the results of MIST to be available in the first quarter of 2006.
According to John Ahern, NMT's president and CEO, "Encouraging preliminary data from our MIST trial recently revealed that 60 percent of migraine patients studied had a right to left shunt, the majority of which were a PFO (patent foramen ovale). The incidence of these shunts, which allow venous blood unfiltered and unmanaged by the lungs to enter the arterial blood circulation, is significantly greater than the general population. This data indicates a strong correlation between PFO and migraine headaches. If MIST determines that PFO closure with NMT's STARFlex implant is an effective treatment for certain migraine headaches, we believe that PFO closure for migraine will be a substantial revenue growth opportunity."
NMT received approval for MIST in the UK in November 2004 and initiated enrollment in January 2005.
Upcoming Events
-
14May
-
23May
-
30May
-
20Jun
-
21Oct